

This Page Is Inserted by IFW Operations
and is not a part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

IMAGES ARE BEST AVAILABLE COPY.

**As rescanning documents *will not* correct images,
please do not report the images to the
Image Problem Mailbox.**



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁴ : A61K 9/10, 31/195, 31/20 A61K 31/70, 37/02	A1	(11) International Publication Number: WO 88/ 01861 (43) International Publication Date: 24 March 1988 (24.03.88)
(21) International Application Number: PCT/US87/02347 (22) International Filing Date: 16 September 1987 (16.09.87) (31) Priority Application Number: 908,447 (32) Priority Date: 17 September 1986 (17.09.86) (33) Priority Country: US (71) Applicant: BAXTER TRAVENOL LABORATORIES, INC. [US/US]; One Baxter Parkway, Deerfield, IL 60015 (US). (72) Inventors: COTTER, Richard ; 1717 Cedar Glen Drive, Libertyville, IL 60048 (US). JOHNSON, Robert, C. ; 1107 Hull Avenue, Westchester, IL 60153 (US). WARD, Michael ; 427 West Stratford Court, McHenry, IL 60050 (US). MADSEN, David, C. ; 600 Ardmore Terrace, Libertyville, IL 60048 (US). VALICEN-TI, Anthony, J. ; 400 Margate Terrace, Deerfield, IL 60015 (US). MENARD, Michael, P. ;		58 George Street, Grayslake, IL 60030 (US). TUCKER, Hugh, N. ; 25950 West Hippler, Barrington, IL 60010 (US). (74) Agents: FENTRESS, Susam, Bennett et al.; One Baxter Parkway, Deerfield, IL 60015 (US). (81) Designated States: AT (European patent), AU, BE (European patent), CH (European patent), DE (European patent), FR (European patent), GB (European patent), IT (European patent), LU (European patent), NL (European patent), SIE (European patent). Published <i>With international search report.</i>
(54) Title: NUTRITIONAL SUPPORT OR THERAPY FOR INDIVIDUALS AT RISK OF UNDER TREATMENT FOR ATHEROSCLEROTIC, VASCULAR, CARDIOVASCULAR, AND/OR THROMBOTIC DISEASES (57) Abstract <p>A nutritional composition for individuals under treatment for or at risk of atherosclerotic, vascular, cardiovascular, and/or thrombotic disease. The composition comprises a protein source; a carbohydrate source; and at least one lipid selected from the group consisting of: gamma-linolenic acid; eicosapentaenoic acid; docosahexaenoic acid; steric acid; and linolenic acid. Both an enteral and parenteral composition are provided.</p>		

- 1 -

SPECIFICATIONNUTRITIONAL SUPPORT OR THERAPY FOR INDIVIDUALS AT
RISK OR UNDER TREATMENT FOR ATHEROSCLEROTIC,
VASCULAR, CARDIOVASCULAR, AND/OR THROMBOTIC DISEASES

5 The present invention relates to
nutritional formulations for the support and therapy
of individuals. More specifically, the present
invention relates to nutritional compositions for
supporting and/or providing therapy to individuals at
10 risk and/or under treatment for atherosclerotic,
vascular, cardiovascular, or thrombotic diseases.

For some time investigators and scientists
have noted a relationship between diet and the heart
function and related systems. There has always been
15 an appreciation for the cardiovascular effects of
obesity and the recognition of widespread prevalence
of undernutrition in hospitalized patients with
cardiovascular derangements. Accordingly, there have
been many attempts to formulate nutritional support
20 for patients at risk for or exhibiting
atherosclerotic, vascular, cardiovascular, and/or
thrombotic diseases. Poindexter, et al, Nutrition in
Congestive Heart Failure, Nutrition In Clinical
Practice (1986) recognize that specific nutritional
25 deficiencies may cause, precipitate, or aggravate
acute heart failure. As Poindexter, et al, point
out, nutritional deficiencies have been significant
factors in the etiology of heart failure in the
Orient and developing countries. It is further noted
30 that nutritional therapy for malnourished cardiac
patients in recent years has been considered
essential supportive therapy.

- 2 -

Patients suffering from long term congestive heart failure have been found to suffer from cardiac cachexia. Other effects of protein-calorie malnutrition on the heart include

5 hypertension, reduced heart rate, reduction in basal metabolic rate and oxygen consumption, atrophy of the heart muscle mass, electrocardiogram (ECG) abnormalities, and heart failure. Furthermore, when congestive heart failure occurs secondary to valvular

10 heart disease that is treated surgically, nutritional status has a notable effect on the surgical outcome. Performing cardiac surgical procedures on patients in a state of nutritional depletion can result in increased morbidity and mortality, compared

15 to adequately nourished patients.

Typically, patients suffering from congestive heart failure are underweight with poor nutritional status. Patients with congestive heart failure and cardiac cachexia frequently exhibit:

20 anorexia and early satiety. Poindexter, et al, state that this is attributed to the natural compensatory mechanism that decreases work of the failing heart. Furthermore, due to hepatic congestion that increases pressure in the abdominal cavity, there is a constant

25 feeling of fullness. Moreover, altered taste sensations and intolerances to food odors limit the patient's desire to eat. Accordingly, liquid nutritional supplements high in nutrient density are desirable. However, as Poindexter notes, this must

30 be tempered with concern about the complications caused by overzealous refeeding of malnourished cardiac patient.

- 3 -

Not only are patients with congestive heart failure and other vascular diseases typically underweight with poor nutritional status, but their energy requirements are greatly in excess of a normal individual's energy requirements. Poindexter, et al, note that energy requirements of a patient with congestive heart failure may be 30-50 percent in excess of basal energy expenditure because of increased cardiac and pulmonary energy expenditure. Indeed, cachectic patients require additional calories for repletion and post-operative cardiac patients require still further increases in caloric intake to meet energy demands. For example, the protein requirement for a normal healthy individual to maintain zero nitrogen balance is 0.5-1.0g/Kg. The patient with congestive heart failure or the post-operative cardiac patient in contrast can require as much as 1.5-2.0g/Kg to maintain nitrogen balance.

Not only is nutrition important in treating the patient with atherosclerotic, vascular, cardiovascular, and/or thrombotic disease but: it is also important in supporting patients at risk of acquiring these diseases. Diet can impact the onset of these diseases in certain individuals.

Accordingly, there is a need for a nutritional composition for supporting and therapeutically treating individuals under treatment for vascular, cardiovascular, or thrombotic diseases. Moreover, there is a need for a nutritional composition for supporting individuals who are at high risk of atherosclerotic, vascular, cardiovascular, and/or thrombotic disease.

- 4 -

The present invention provides a nutritional composition for supporting and/or providing therapy to individuals at risk or under treatment for vascular, cardiovascular, or thrombotic diseases. The formulation can be administered either
5 as an enteral product or parenterally.

As an enteral product, the formulation comprises a protein source, a carbohydrate source, a fat source, and electrolytes. The protein source
10 preferably includes a high biological value protein, an amino acid solution, branched-chain amino acids, and carnitine. The amino acid solution is designed to provide the essential, conditionally essential, and non-essential amino acids necessary for
15 efficacious protein metabolism in the face of cardiovascular or thrombotic disease states. The nutritional composition also contains a carbohydrate source. The carbohydrate source preferably includes xylitol and a glucose base carbohydrate.

20 The lipid component of the nutritional composition comprises long chain triglycerides and medium chain fatty acids. The long chain triglycerides encompass triglycerides containing fatty acids of 11 to 26 carbons in length. The
25 medium chain fatty acids preferable in the present invention are those that are 6 to 10 carbons in length.

Preferably, the long chain triglycerides comprise marine oils and/or gamma-linolenic acid (GLA) and stero~~donic~~ acid. Preferably, the marine
30 oils include linolenic acid and large amounts of two other members of the omega three family: eicosapentaenoic acid (EPA) and docosahexaenoic acid

- 5 -

(DHA). These fatty acids are incorporated into cell membranes and serum and give rise to metabolites of the omega-three metabolic pathways. Preferably the long chain triglycerides comprise from approximately 50% to about 25% of the lipid component and the medium chain fatty acids comprises from approximately 75% to about 50% of the lipid component. If GLA is utilized with marine oil preferably approximately three times as much marine oil is used as GLA.

10 Preferably the protein source comprises approximately 15 to about 25% of the caloric source of the enteral nutritional composition. Most preferably the protein source comprises approximately 20% of the caloric source of the enteral nutritional composition. Preferably, the carbohydrate source 15 comprises approximately 40% to about 75% of the caloric source of the enteral nutritional composition. Most preferably, the carbohydrate source comprises approximately 50% of the caloric source of the enteral nutritional composition.. 20 Preferably the lipid component comprises approximately 10% to about 40% of the caloric source of the enteral nutritional composition. Most preferably the lipid component comprises 25 approximately 30% of the caloric source of the enteral nutritional composition.

The parenteral regimen for the composition for providing nutritional support or therapy for individuals at risk or under therapy for 30 atherosclerotic, vascular, cardiovascular, and/or thrombotic disease is preferably modular. However, the parenteral regimen can be delivered modularly or premixed. As a modular regimen the parenteral

- 6 -

product includes an injectable solution of: a lipid emulsion; a carbohydrate; carnitine; branched-chain amino acids; and amino acids.

Preferably, the lipid emulsion for
5 injection includes approximately 5 to about 20% of a triacylglycerol oil containing approximately 5 to about 80% eicosapentaenoic acid (EPA) and/or approximately 5 to about 80% gamma-linolenic acid (GLA) and approximately 3 to about 25% sterodomic
10 acid (6, 9, 12, 15-otadecateraenoic acid), with approximately 0.4 to about 1.6% egg or soy beam phospholipid and approximately 2.25% of glycerol or other physiologically acceptable tonicity agent, adjusted to physiological pH with sodium hydroxide.
15 The remaining component(s) of the lipid emulsion is either water or water with medium chain triglycerides.

The present invention provides a nutritional composition that affords a rational,
20 scientific diet or supplement for individuals at high risk or under treatment for atherosclerotic, tvascular, cardiovascular, and/or thrombotic diseases. The formulation is designed to slow the progression of these diseases, and prevent the onset
25 of acute episodes that can result in the death of such patients. To this end, the present invention provides a composition that includes nutritional substrates that have been shown to effect various biochemical and physiological parameters of vascular,
30 cardiovascular and blood systems. The formulation can be administered either as an enteral product or parenterally.

- 7 -

As an enteral product, the formulation comprises a protein source, a carbohydrate source, a fat source, and preferably electrolytes. The protein source preferably includes a high biological value protein, an amino acid solution, branched-chain amino acids, and carnitine. The high biological value protein comprises the base component. Although any high biological value protein can be utilized preferably the high biological value protein is lactalbumin or soy protein. Whole protein or hydrolysates can be utilized.

The amino acid solution is designed to provide the essential, conditionally essential, and non-essential amino acids necessary for efficacious protein metabolism in the face of cardiovascular or thrombotic disease states. The amino acid solution preferably includes: L-Arginine; L-Leucine; L-Isoleucine; L-Lysine; L-Valine; L-Phenylalanine; L-Histidine; L-Threonine; L-Methionine; L-Tryptophan; L-Alanine; L-Proline; L-Serine; L-Tyrosine; and amino acetic acid. An example of an amino acid solution formulation that will function satisfactorily is TRAVASOL^R marketed by Travenol Laboratories, Deerfield, Illinois. Of course, depending upon requirements not all of the amino acids must be included in the solution. Of course, other nutrients such as, for example, biologically available sources of taurine and cysteine can be added. Preferably the arginine:lysine ratio is between approximately about 0.7:1 to 1.25:1. Most preferably the ratio is approximately 1:1. Clinical and experimental evidence has shown that an arginine:lysine ratio of 1

- 8 -

to 1 is associated with lower plasma cholesterol levels.

The amino acid and base protein, i.e., high biological value protein, is combined with
5 branched-chain amino acids to achieve a final concentration of approximately 45 to 55 percent branched-chain amino acids (w/w). Most preferably the final concentration of branched-chain amino acids is 50 percent of total protein and amino acid
10 content. The branched-chain amino acid mixture that function satisfactorily is that capable of maintaining essential intake of all three branched-chain amino acids to meet nutritional requirements. The branched-chain amino acids
15 Isoleucine, Leucine, and Valine are preferably included in a 1:1:1 molar ratio. An example of such a branched-chain amino acid formula is BRANCHAMIN^R marketed by Travenol Laboratories, Deerfield, Illinois. Observations on rats and dogs demonstrate
20 that these cardiac muscles depend more on branched-chain amino acids than on all other amino acids. As previously stated, other amino acids can be utilized; for example, in neonates and infants it may be desirable to include taurine.

25 Preferably glycine should be supplemented to the protein source, if necessary, to obtain levels typically found in soy protein. It has been found that higher levels of plasma glycine are associated with lowered levels of plasma cholesterol.

30 The protein source also preferably includes L-carnitine. The L-carnitine is added to achieve a final concentration of approximately 15 to 40 mg/g of total protein. Most preferably the final

- 9 -

concentration of L-carnitine is 25 mg/g of total protein. Many publications have shown that damaged cardiac muscle functions better when supplemented with L-carnitine.

5 The nutritional composition also contains a carbohydrate source. The carbohydrate source preferably includes xylitol and a glucose-based carbohydrate. In a preferred embodiment the carbohydrate source includes maltodextrin and
10 xylitol. The glucose substrate and xylitol are preferably present in a 1:1 ratio by weight. The carbohydrate source can also include ribose. In a preferred embodiment, the composition contains maltodextrin, xylitol, and ribose in a preferred
15 ratio of approximately 1:1:.066 by weight. In another embodiment, the composition contains maltodextrin and xylitol preferably in a ratio of approximately 1:1 by weight.

 The use of carbohydrates such as xylitol or
20 ribose in nutritional support of individuals susceptible to and/or under treatment for cardiovascular disease is based upon the unique pathways for the metabolism of these compounds. Xylitol is a naturally occurring intermediate in the
25 glucuronic acid-xylulose cycle, and may also be metabolized through the generation of the intermediate compound xylulose to form ribose. Accordingly, the administration or ingestion of the xylitol, xylulose, and/or ribose provides conversions
30 of these intermediates to glucose. By providing a glucose-based carbohydrate source, i.e., maltodextrin, conversion of these compounds to glucose is minimized. The administration of a 1 to 1

- 10 -

ratio of glucose substrates with xylitol and ribose represents an effective means to maximize glucose production with minimal insulin elevation, while enhancing adenine nucleotide synthesis for this:
5 patient population.

The effect of ribose on cardiac function and ischemic events may be related to several specific functions of the compound. Administration of ribose to cardiac tissue following oxygen
10 deprivation has been demonstrated to result in a 90% increase in the de novo synthesis of myocardial adenine nucleotides, as well as in the elevation of 5-phosphoribosyl-1-pyrophosphate (PRPP) specific pool in myocardial tissue. Continuous infusion of ribose
15 has been demonstrated to result in a 13-fold increase in myocardial adenine nucleotide synthesis. Such elevations have further been demonstrated to reduce the occurrence of cell lesions in the myocardium.

It has been suggested that cellular
20 depletion of compartmentalized ATP may be primarily responsible for the pathological effects of the ischemic event, through an imbalance between subcellular phosphocreatine and compartmentalized ATP. ATP may also serve as a modulator of myocardial
25 cell function, responsible for potassium exchange and calcium:sodium exchange. These reactions require higher concentrations of ATP than those required for the PRPP pool alone. Demonstration of a marked effect of ribose administration on protection against
30 isoproterenol-induced myocardial cell damage further supports the hypothesis for a role in cellular depletion of adenine nucleotides in the progression of cardiac necrosis.

- 11 -

The lipid component of the nutritional composition comprises long chain triglycerides and medium chain fatty acids. Preferably, the long chain triglycerides comprise "marine oils" and/or
5 gamma-linolenic acid of 11 to 26 carbons in length. These fatty acids can be both saturated and unsaturated in nature. It has been shown that monounsaturated fatty acids are effective in lowering plasma cholesterol. Accordingly, preferably
10 monounsaturated fatty acids are utilized as a component of these lipid substrates.

The medium chain fatty acids preferable in the present invention are those that are 6 to 10 carbons in length. These medium chain fatty acids
15 are a superior energy source for the cardiac muscle cells. The fatty acids can be provided to patients as free fatty acids, mono-, di- or triglycerides. Medium chain fatty acids are chemically unique in that in the absence of cytoplasmic medium chain fatty
20 acyl CoA synthetase they are able to pass through the inner mitochondrial membrane unhindered. Medium chain fatty acyl CoA synthetase does exist in the mitochondria and activates the fatty acids once they have crossed the inner membrane. These activated
25 fatty acids are then rapidly metabolized.

In contrast, long chain fatty acids, i.e., those fatty acids having 11 to 26 carbons, due to their chemical nature cannot cross the inner
mitochondrial membrane without being first activated
30 by cytoplasmic long chain fatty acyl CoA synthetase, a rate limiting process. The long chain fatty acids must then undergo obligatory conversion to a

- 12 -

carnitine transport form for entry into the mitochondria for metabolism.

Medium chain fatty acids combine their unique ability to cross the mitochondria membrane with the unique biochemical milieu of the cardiac cell. The cardiac muscle lacks cytoplasmic medium chain acyl CoA synthetase and the ability to activate medium chain fatty acids. Thus, medium chain fatty acids rapidly enter the mitochondria and supply energy in these cells directly. Long chain fatty acids cannot do this because of their necessary cytoplasmic activation and the slower carnitine transport in this organ.

The long chain triglycerides preferably comprise marine oils and/or gamma-linolenic acid (GLA) and/or steroedonic acid. The marine oils preferably include linolenic acid and large amounts of two other members of the omega three family: eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA). These fatty acids are incorporated into cell membranes and serum lipids and give rise to metabolites of the omega-three metabolic pathways. GLA is an omega-6 fatty acid and is a precursor to the 1-series prostaglandins.

Preferably the long chain triglycerides comprise from approximately 50% to about 25% of the lipid component and the medium chain fatty acids comprises from approximately 75% to about 50% of the lipid component. If GLA is utilized with marine oil, preferably approximately three times as much marine oil is used as GLA.

All cells utilize these fatty acids to form various prostaglandins and leukotrienes. When fatty

- 13 -

acids are released from cell membranes, lipoxygenase and cyclooxygenase mediate further metabolic activity. Although EPA is a relatively poor substrate for lipoxygenase and cyclooxygenase, it appears to have a high binding affinity and thereby inhibits arachidonic acid conversion by these enzymes. An added benefit of the omega three fatty acid pathway lies in the physiological activity of their cellular products (See Table I - PGI₂ = 2-series prostacyclin; PGI₃ = 3-series prostacyclin; TXA₂ = 2-series thromboxane; and TXA₃ = 3-series thromboxane).

TABLE I

15	Cell	Fatty Acid	Product	Physiological Actions
20	Endothelial	Arachidonic	PGI ₂	Lower platelet activity: vasodilation
		Eicosapentaenoic	PGI ₃	Lower platelet activity: vasodilation
25	Platelet	Arachidonic	TXA ₂	Platelet hyper- activity: vasocom- striction
30		Eicosapentaenoic	TXA ₃	Lower platelet activity: vasocomstric- tion

- 14 -

In most subjects who consume such diets, total serum cholesterol, LDL cholesterol, and triglycerides are significantly lowered, whereas HDL cholesterol concentrations are elevated. This
5 pattern of change would be one thought to be less atherogenic and the thrombogenic.

Studies conducted with human platelets utilizing pure EPA and arachidonic acid support the role of the balance of EPA and arachidonic acid as
10 the critical factor in controlling platelet activators and vessel constriction.

The electrolytes component of the present invention preferably includes sodium, potassium, chloride, calcium, magnesium, and phosphorus.

15 Preferably the protein source comprises approximately 15 to about 25% of the caloric source of the enteral nutritional composition. Most preferably the protein source comprises approximately 20% of the caloric source of the enteral nutritional
20 composition. Preferably, the carbohydrate source comprises approximately 40% to about 75% of the caloric source of the enteral nutritional composition. Most preferably, the carbohydrate source comprises approximately 50% of the caloric
25 source of the enteral nutritional composition. Preferably the lipid component comprises approximately 10% to about 40% of the caloric source of the enteral nutritional composition. Most preferably the lipid component comprises
30 approximately 30% of the caloric source of the enteral nutritional composition.

- 15 -

By way of example, and not limitation, two preferred enteral cardiac formulations will now be set forth.

TABLE II

CARDIAC FORMULATION

5	Form:	Liquid
	Concentration:	2.0 kcal/ml
10	Protein Source:	Lactalbumin L-Carnitine Enhance BCAA Hi Arg: lys ratio Inc. Glycine
15	Gm/Liter	100
	% Cal	20
	Carbohydrate Source:	Maltodextrin Xylitol, Ribose
20	Ratio:	1.0:1.0:.066
	Gm/Liter	121,121,8
	% Cal	50
25	Fat Source:	Marine Oil (MO) GLA, MCT
	Gm/Liter MCT&LCT	57.7
	MO:GLA:MCT	3:1:12
30	% Cal	30

- 16 -

<hr/>		
	Electrolytes:	
	Na/Liter	500mg
		21.8mEq
5	K/Liter	1000mg
		35.4mEq
	Cl/Liter	1000mg
	Ca/Liter	1200mg
	P/Liter	1000mg
10	Mg/Liter	600mg
<hr/>		
TABLE III		
CARDIAC FORMULATION		
<hr/>		
	Form:	Liquid
15	<hr/>	
	Concentration:	2.0 kcal/ml
<hr/>		
	Protein Source:	Lactalbumin
		L-Carnitine
20		Enhance BCAA
		Hi Arg: lys ratio
		Inc. Glycine
	Gm/Liter	100
	% Cal	20
25	<hr/>	
	Carbohydrate Source:	Maltodextrin
		Xylitol
	Ratio:	1.0:1.0
	Gm/Liter	125,125
30	% Cal	50
<hr/>		
	Fat Source:	Marine Oil (MO)
		GLA, MCT

- 17 -

Gm/Liter MCT&LCT	57.7
MO:GLA:MCT	3:1:12
% Cal	30

5 Electrolytes:

	Na/Liter	500mg
		21.8mEq
	K/Liter	1000mg
		35.4mEq
10	Cl/Liter	1000mg
		28.3mEq
	Ca/Liter	1200mg
	P/Liter	1000mg
	Mg/Liter	600mg

15 The parenteral regimen for the composition for providing nutritional support or therapy for individuals at risk or under therapy for vascular, cardiovascular, or thrombotic disease is preferably modular. However, the parenteral regimen can be

20 premixed before use. The parenteral regimen solution for injection contains: a lipid emulsion; a carbohydrate solution; carnitine; branched-chain amino acids; and amino acids.

25 Preferably, the lipid emulsion for injection includes approximately 5 to about 20% of a triacylglycerol oil containing approximately 5 to about 80% eicosapentaenoic acid (EPA) and/or approximately 5 to about 80% gamma-linolenic acid (GLA) and approximately 3 to about 25% sterodonic

30 acid (6, 9, 12, 15-octadecatetraenoic acid), with approximately 0.4 to about 1.6% egg or soy bean phospholipid and approximately 2.25% of glycerol or other physiologically acceptable tonicity agent,

- 18 -

adjusted to physiological pH with sodium hydroxide. Water or water and medium chain triglycerides comprise the remainder of the lipid emulsion. If medium chain triglycerides are used they comprise no more than 30% (w/v) of the lipid emulsion.

The carbohydrate injection solution preferably contains glucose and xylitol in an approximately 1:1 ratio by weight. The solution can contain in an embodiment approximately 3.3% (w/v) ribose.

To the branched-chain amino acid injection solution can be added any other amino acid capable of necessary to meet nutritional requirements. The branched-chain amino acid injection solution contains Isoleucine, Leucine, and Valine, preferably in a 1:1:1 molar ratio.

The solution for injection of amino acids can contain essential, non-essential, and conditionally essential amino acids. Preferably the solution includes: L-Arginine; L-Leucine; L-Isoleucine; L-Lysine; L-Valine; L-Phenylalanine; L-Histidine; L-Threonine; L-Methionine; L-Tryptophan; L-Alanine; L-Proline; L-Serine; L-Tyrosine; and amino acetic acid. However, the solution can contain less than all these amino acids, or other nutrients; such as, for example, taurine and cysteine. An example of such an amino acid solution and the relevant proportions of each amino acids is TRAVASOL^R marketed by Travenol Laboratories, Deerfield, Illinois.

By way of example, and not limitation, contemplated examples will now be given.

- 19 -

Example One

This contemplated example demonstrates the use of the parenteral cardiac formulation in providing nutrition and therapy to a patient suffering cardiovascular disease.

A middle-aged male patient is admitted to intensive care following an acute myocardial infarction. Among the therapies administered would be the parenteral cardiac formulation as part of a continuous intravenous infusion. The parenteral cardiac formula includes: a lipid emulsion injection; a carbohydrate injectable solution; injectable carnitine; injectable branched-chain amino acid solution; and an injectable amino acid solution. The lipid emulsion for injection includes 10% of a triacylglycerol oil containing 15% eicosapentaenoic acid (EPA) and 5% gamma-linolenic acid (GLA) and 5% sterodonic acid with 1.2% soybean phospholipid and approximately 2.25% of glycerol and water. The carbohydrate injection solution contains glucose and xylitol in an approximately 1:1 ratio by weight. The branched-chain amino acid injection solution contains Isoleucine, Leucine, and Valine, in a 1:1:1 molar ratio. The amino acid solution was TRAVASOL^R. The key critical features of this patient's clinical profile include:

cardiac ischemia with hyperreactive platelets that can be easily triggered to aggregate, leading to a life-threatening secondary event involving thrombus formation and vasoconstriction of the coronary artery at the site of activation, increased

- 20 -

vascular tone and a predisposition to
vascular spasm.

As a result of this cardiac parenteral formulation,
the patient's cardiac muscle tissue would have
5 available energy and protein substrates and their
platelets would be far less reactive within hours of
the onset of I.V. administration. Furthermore, the
balance of the 2-series prostacyclins and 3-series
prostacyclin/2-series thromboxane ratio would begin
10 to shift in a favorable direction, leading to a
reduced risk of vascular spasm.

Example Two

This same patient, as described in example
one, recovers and is sent home to follow a strict
15 regimen. He has advanced atherosclerosis, the
sequellae of which include hypertension, elevated
serum triglycerides and LDL, VLDL, and total
cholesterol concentrations, low serum HDL cholesterol
concentration, and a very high risk of stroke,
20 myocardial infarction, or other thrombotic events.

Doctors focus on dietary control of this
disease process, to supplement prescribed
medications. The cardiac enteral diet set forth in
Table II as a nutritional supplement provides
25 necessary cardiac muscle nutrition as well as the
therapeutic effects of EPA/DHA. Consumed on a daily
basis, this diet would:

1. provide specialized cardiac muscle
protein;
- 30 2. provide carbohydrate and calorie
nutrition;
3. lower serum triglyceride and LDL, VLDL,
and total cholesterol concentrations;

- 21 -

4. markedly reduce platelet reactivity, leading to reduced incidence of thromboxane and serotonin release by platelets (vasoactive stimulators and platelet activators) as well as platelet derived growth factor release (a known atherogenic factor);
5. lower systolic blood pressure, another factor associated with atherogenesis.

10 Example Three

In this contemplated example, a patient with cardiovascular disease requires a vascular graft. The highest risk for graft-associated thrombosis occurs within the first week following graft placement. Since this is a platelet/white blood cell-mediated event, placing this patient on a combined parenteral (set forth in Example One) and enteral (Table II) cardiac formulation for 7-10 days, while in recovery, will markedly dampen both platelet and white blood cell reactivity as well as provide essential nutritional support.

Following release from hospital, this patient could continue with the daily consumption of the parenteral and/or enteral formulation to maintain a low thrombogenic potential.

25 Example Four

In this contemplated example, an elderly patient following hip surgery is committed to several weeks of bed rest. There is a recognized marked thrombotic tendency following this procedure, partly due to the surgery itself, and partly to the prolonged vascular stasis resulting from the elimination of physical activity.

- 22 -

A regimen of combined enteral (Table II) and parenteral (set forth in Example One) cardiac formulation for a week following surgery, and a continuation of the enteral formulation during the remainder of the recovery period, will not only dampen the thrombotic tendency, but also will provide essential nutrients to support the healing process in this elderly patient.

It should be understood that various changes and modifications to the presently preferred embodiments described herein will be apparent to those skilled in the art. Such changes and modifications can be made without departing from the spirit and scope of the present invention and without diminishing its attendant advantages. It is therefore intended that such changes and modifications be covered by the appended claims.

- 23 -

WE CLAIM:

1. A nutritional composition for individuals under treatment for or at risk of atherosclerotic, vascular, cardiovascular, and/or thrombotic disease comprising:
 - a nutritionally effective amount of a protein source;
 - a nutritionally effective amount of a carbohydrate source;
 - 10 a nutritionally effective amount of medium chain fatty acids; and
 - a nutritionally effective amount of at least one lipid selected from the group consisting of: gamma-linolenic acid; sterodonic acid; and marine oil.
- 15 2. The nutritional composition of claim 1 wherein the marine oil contains at least one oil selected from the group consisting of eicosapentaenoic acid; docosahexaenoic acid; and
20 linolenic acid.
3. The nutritional composition of claim 1 wherein the protein source includes;
 - a high biological value protein;
 - amino acids;
 - 25 branched-chain amino acids; and
 - L-carnitine.
4. The nutritional composition of claim 3 wherein the high biological value protein is chosen from the group consisting of lactalbumin and soy
30 protein.
5. The nutritional composition of claim 3 wherein the amino acids include: L-Arginine; L-Leucine; L-Isoleucine; L-Lysine; L-Valine;

- 24 -

L-Phenylalanine; L-Histidine; L-Threonine; L-Methionine; L-Tryptophan; L-Alanine; L-Proline; L-Serine; L-Tyrosine; and amino acetic acid.

5 6. The nutritional composition of claim 3 wherein the branched-chain amino acids include: isoleucine, leucine, and valine.

 7. The nutritional composition of claim 1 wherein the carbohydrate source includes a glucose substrate and xylitol.

10 8. The nutritional composition of claim 7 wherein the glucose substrate is maltodextrin.

 9. The nutritional composition of claim 8 wherein the carbohydrate source includes ribose.

15 10. The nutritional composition of claim 1 wherein the medium chain fatty acid comprise approximately 50 to about 75% of the total lipid content of the composition.

20 11. The nutritional composition of claim 1 including a therapeutically effective amount of electrolytes.

 12. An enteral composition comprising:
 a protein source representing
 approximately 15 to about 25% of the
 caloric source of the composition, the
25 protein source including essential, conditionally essential, and nonessential amino acids, branched-chain amino acids, and a high biological value protein;
30 a carbohydrate source representing
 approximately 40% to about 75% of the
 caloric source of the composition; and

- 25 -

a lipid component representing

approximately 10% to about 40% of the caloric source of the composition, the lipid component including medium chain fatty acids and at least one lipid selected from the group consisting of: gamma-linolenic acid; eicosapentaenoic acid; docosahexaenoic acid; linolenic acid and steroidal acid.

10

13. The enteral composition of claim 12 wherein the amino acids include: L-Arginine; L-Leucine; L-Isoleucine; L-Lysine; L-Valine; L-Phenylalanine; L-Histidine; L-Threonine; L-Methionine; L-Tryptophan; L-Alanine; L-Proline; L-Serine; L-Tyrosine; and amino acetic acid.

15

14. The enteral composition of claim 12 wherein the branched-chain amino acids include: isoleucine, leucine, and valine.

20

15. The enteral composition of claim 12 wherein the carbohydrate source includes a glucose substrate and xylitol.

16. The enteral composition of claim 15 wherein the glucose substrate is maltodextrin.

25

17. The enteral composition of claim 16 wherein the carbohydrate source includes ribose.

18. The enteral composition of claim 12 wherein the protein source includes L-carnitine.

30

19. The enteral composition of claim 12 including electrolytes.

20. The enteral composition of claim 12 wherein the high biological value protein is chosen

- 26 -

from the group consisting of lactalbumin and soy protein.

21. The enteral composition of claim 12 wherein the medium chain fatty acids comprise approximately 50 to about 75% of the lipid component.

22. The enteral composition of claim 12 wherein the lipid component includes gamma-linolenic acid, eicosapentaenoic acid, docosahexaenoic acid, sterodonic acid and linolenic acid.

23. A parenteral regimen for cardiac therapy comprising:

a therapeutically effective amount of an injectable lipid emulsion including a triacylglycerol oil having at least one of the lipids selected from the group consisting of eicosapentaenoic acid, gamma-linolenic acid and sterodonic acid, and a phospholipid chosen from the group consisting of egg phospholipid or soybean phospholipid, and glycerol and water;

a therapeutically effective amount of an injectable solution of glucose and xylitol;

a therapeutically effective amount of L-carnitine;

a therapeutically effective amount of an injectable solution of branched-chain amino acids; and

a therapeutically effective amount of an injectable solution of amino acids.

- 27 -

24. The parenteral regimen of claim 23 wherein the triacylglycerol oil comprises approximately 5 to about 20% of the lipid emulsion.

5 25. The parenteral regimen of claim 23 wherein the triacylglycerol oil includes approximately 5 to about 80% eicosapentaenoic acid.

26. The parenteral regimen of claim 23 wherein the triacylglycerol oil includes approximately 5 to about 80% gamma-linolenic acid.

10 27. The parenteral regimen of claim 23 wherein the triacylglycerol oil includes approximately 3 to about 35% sterodonic acid.

28. The parenteral regimen of claim 23 wherein the amino acids include: L-Arginine;
15 L-Leucine; L-Isoleucine; L-Lysine; L-Valine;
L-Phenylalanine; L-Histidine; L-Threonine;
L-Methionine; L-Tryptophan; L-Alanine; L-Proline;
L-Serine; L-Tyrosine; and amino acetic acid.

29. The parenteral regimen of claim 23
20 wherein the branched-chain amino acids include:
isoleucine, leucine, and valine.

30. The parenteral regimen of claim 23 wherein the lipid emulsion, glucose and xylitol,
L-carnitine, branched-chain amino acids and amino
25 acids are premixed before infusion into a patient.

31. The parenteral regimen of claim 23 wherein the lipid emulsion includes medium chain triglycerides.

32. A method for providing nutritional
30 support for patients under treatment or at high risk
for atherosclerotic, vascular, cardiovascular and/or
thrombotic diseases which method comprises

- 28 -

administering the nutritional composition of claims
12 and 23.

INTERNATIONAL SEARCH REPORT

International Application No PCT/US87/02347

I. CLASSIFICATION OF SUBJECT MATTER (if several classification symbols apply, indicate all) ¹ According to International Patent Classification (IPC) or to both National Classification and IPC IPC (4): A61K 9/10, 31/195, 31/20, 31/70, 37/02 US CL: 514/558, 560, 561, 562, 564, 2, 23, 824, 943; 424/95		
II. FIELDS SEARCHED <div style="text-align: center; border-top: 1px solid black; border-bottom: 1px solid black; margin: 5px 0;">Minimum Documentation Searched ⁴</div> <div style="display: flex; justify-content: space-between;"> <div style="width: 30%; border-bottom: 1px solid black;">Classification System </div> <div style="width: 65%; border-bottom: 1px solid black;">Classification Symbols</div> </div> <div style="margin-top: 10px;"> U.S. 514/558, 560, 561, 562, 564, 2, 23, 824, 943; 424/95 </div> <div style="margin-top: 10px; font-size: small;"> Documentation Searched other than Minimum Documentation to the Extent that such Documents are Included in the Fields Searched ⁴ </div>		
III. DOCUMENTS CONSIDERED TO BE RELEVANT ¹⁴		
<div style="border-bottom: 1px solid black; margin-bottom: 5px;">Category ⁸</div> <div style="border-bottom: 1px solid black; margin-bottom: 5px;">P, X Y</div> <div style="border-bottom: 1px solid black; margin-bottom: 5px;">Y</div> <div style="border-bottom: 1px solid black; margin-bottom: 5px;">Y</div> <div style="border-bottom: 1px solid black; margin-bottom: 5px;">Y</div>	<div style="border-bottom: 1px solid black; margin-bottom: 5px;">Citation of Document, ¹⁶ with indication, where appropriate, of the relevant passages ¹⁷</div> <div style="border-bottom: 1px solid black; margin-bottom: 5px;">US, A, 4,687,782 (BRANTMAN), 18 August 1987, see the entire document.</div> <div style="border-bottom: 1px solid black; margin-bottom: 5px;">US, A, 4,526,902 (RUBIN), 2 July 1985, see the entire document.</div> <div style="border-bottom: 1px solid black; margin-bottom: 5px;">US, A, 4,438,144, (BLACKBURN), 20 March 1984, see entire document.</div> <div style="border-bottom: 1px solid black; margin-bottom: 5px;">US, A, 4,434,160, (JERETIN ET AL), 28 February 1984, see the entire document.</div>	<div style="border-bottom: 1px solid black; margin-bottom: 5px;">Relevant to Claim No. ¹⁴</div> <div style="border-bottom: 1px solid black; margin-bottom: 5px;">1-6, 10-14, 18-22 11-32</div> <div style="border-bottom: 1px solid black; margin-bottom: 5px;">11-32</div> <div style="border-bottom: 1px solid black; margin-bottom: 5px;">11-32</div> <div style="border-bottom: 1px solid black; margin-bottom: 5px;">11-32</div>
<div style="display: flex; justify-content: space-between; font-size: x-small;"> <div style="width: 45%;"> <p>¹⁰ Special categories of cited documents:</p> <p>"A" document defining the general state of the art which is not considered to be of particular relevance</p> <p>"E" earlier document but published on or after the international filing date</p> <p>"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)</p> <p>"O" document referring to an oral disclosure, use, exhibition or other means</p> <p>"P" document published prior to the international filing date but later than the priority date claimed</p> </div> <div style="width: 45%;"> <p>"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention</p> <p>"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step</p> <p>"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art</p> <p>"Δ" document member of the same patent family</p> </div> </div>		
IV. CERTIFICATION		
Date of the Actual Completion of the International Search ¹ <div style="text-align: center; font-size: large;">30 November 1987</div>	Date of Mailing of this International Search Report ¹ <div style="text-align: center; font-size: large;">10 DEC 1987</div>	
International Searching Authority ¹ <div style="text-align: center;">ISA/US</div>	Signature of Authorized Officer ¹⁸ <div style="text-align: center;"> J. Stone </div>	